Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven β-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. β-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression.
1. A high capacity adenoviral expression vector capable of enhancing the expression of a transgene, comprising:
a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and
the transgene,
wherein the polynucleotide is fused to the 3′ end of the transgene and is not translated into an amino acid sequence.
2. The expression vector of claim 1 , further comprising an mCMV promoter.
3. The expression vector of claim 2 , wherein the mCMV promoter is operably linked to the transgene and the polynucleotide.
4. A method of enhancing the expression of a transgene, comprising:
providing a high capacity adenoviral expression vector comprising: a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and the transgene;
introducing the expression vector into a cell; and
maintaining the cell under conditions permitting increased expression of the transgene,
wherein the polynucleotide is fused to the 3′ end of the transgene and is not translated into an amino acid sequence.
5. The method of enhancing the expression of a transgene of claim 4 , wherein the cell is maintained in vivo.
6. The method of enhancing the expression of a transgene of claim 4 , wherein the cell is maintained in vitro.
7. The method of enhancing the expression of a transgene of claim 4 , wherein the expression vector further comprises an mCMV promoter.
8. The method of enhancing the expression of a transgene of claim 7 , wherein the mCMV promoter is operably linked to the polynucleotide and the transgene.
9. A pharmaceutical preparation, comprising:
a high capacity adenoviral expression vector capable of enhancing the expression of a transgene, comprising:
a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and the transgene; and
a pharmaceutically acceptable carrier,
wherein the polynucleotide is fused to the 3′ end of the transgene and is not translated into an amino acid sequence.
10. The pharmaceutical preparation of claim 9 , wherein the expression vector further comprises an mCMV promoter.
11. The pharmaceutical preparation of claim 10 , wherein the mCMV promoter is operably linked to the polynucleotide and the transgene.
12. A kit for enhanced expression of a transgene, comprising:
a high capacity adenoviral expression vector, comprising: a polynucleotide consisting of base pairs 196 through 1131 of SEQ ID NO: 1; and the transgene;
a pharmaceutically acceptable carrier; and
instructions for use,
wherein the polynucleotide is fused to the 3′ end of the transgene and is not translated into an amino acid sequence.
13. The kit for enhanced expression of a transgene of claim 12 , wherein the expression vector further comprises an mCMV promoter.
14. The kit for enhanced expression of a transgene of claim 13 , wherein the mCMV promoter is operably linked to the polynucleotide and the transgene.
15. The kit for enhanced expression of a transgene of claim 12 , wherein the kit is configured for in vivo expression of the transgene.
16. The kit for enhanced expression of a transgene of claim 12 , wherein the kit is configured for in vitro expression of the transgene.